Compare HLIO & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIO | ADMA |
|---|---|---|
| Founded | 1970 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1996 | 2012 |
| Metric | HLIO | ADMA |
|---|---|---|
| Price | $68.51 | $10.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $94.67 | $17.00 |
| AVG Volume (30 Days) | 350.8K | ★ 3.1M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 23.93 | N/A |
| EPS | ★ 1.25 | 0.35 |
| Revenue | ★ $200,727,000.00 | $42,219,783.00 |
| Revenue This Year | $6.91 | $4.93 |
| Revenue Next Year | $5.86 | $17.59 |
| P/E Ratio | $55.10 | ★ $29.14 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $49.00 | $7.21 |
| 52 Week High | $95.05 | $20.46 |
| Indicator | HLIO | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 60.38 |
| Support Level | $66.25 | $9.23 |
| Resistance Level | $69.41 | $11.42 |
| Average True Range (ATR) | 1.78 | 0.39 |
| MACD | 0.25 | 0.04 |
| Stochastic Oscillator | 27.77 | 81.96 |
Helios Technologies Inc is an industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic components and systems used to transmit power and control force, speed, and motion. There are two categories based on Hydraulic system architecture: MCT and FCT. The Electronics segment provides complete, fully-tailored display and control solutions for engines, engine-driven equipment, specialty vehicles, therapy baths, and traditional and swim spas. The company generates the majority of its revenue from the Hydraulics segment. Geographically, the company generates key revenue from the Americas region.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.